| Literature DB >> 23752467 |
Jiří Václavík1, Petr Sot, Beáta Vilhanová, Jan Pecháček, Marek Kuzma, Petr Kačer.
Abstract
This review is oriented toward the asymmetric transfer hydrogenation (ATH) ofEntities:
Mesh:
Substances:
Year: 2013 PMID: 23752467 PMCID: PMC6270592 DOI: 10.3390/molecules18066804
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Schematic representation of the ATH of cyclic and acyclic imines and ketones on [RuCl(η6-arene)(N-arylsulfonyl-DPEN)] in the presence of a suitable hydrogen source (isopropanol or HCOOH-triethylamine).
Scheme 2Pre-column derivatization of chiral substituted tetrahydroisoquinolines with (−)-(1R)-menthyl chloroformate. The diastereomeric carbamates can be resolved on an achiral GC column and in this way, enantiomeric excess can be determined.
Figure 1Schematic representation of the influence of individual parameters on the reaction rate (blue solid line) and/or enantioselectivity (green dashed line) of the ATH of 1-methyl-3,4-dihydroisoquinoline on [RuCl(η6-arene)(TsDPEN)] [19].
Figure 2Examples of reported N-aryl and N-alkylsulfonyl diamine ligands.
Figure 3P,P and N,N ligands with spacers of different length.
Figure 4Examples of reported N'-alkylated diamine ligands.
Figure 5Examples of tethered complexes of Wills and Ikariya.
Figure 6Examples of (a) 1-alkyl- and 1-aryl-DHIQs and (b) methoxylated derivatives of 1-methyl-DHIQ.
Scheme 3Proposed mechanism of Ru-hydride formation from the Ru-solvate (i.e., protonated 16e− complex) and formate ion.
Figure 7Two diastereomers of [RuH(η6-p-cymene)(S,S)-TsDPEN]. The structures differ by configuration on the Ru atom, while both feature the (S,S)-TsDPEN ligand.
Figure 8Examples of pharmaceutical products synthesized via ATH or AH using [RuCl(η6-arene)(N-arylsulfonyl-DPEN)] (the chiral building blocks obtained by these reactions are shown in green).
Scheme 4Two synthetic pathways giving (R)-5'-methoxylaudanosine.